# Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

> **NCT00388063** · PHASE2 · COMPLETED · sponsor: **Callisto Pharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Atiprimod

## Key facts

- **NCT ID:** NCT00388063
- **Lead sponsor:** Callisto Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2007-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00388063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00388063, "Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00388063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*